Quick Answer
Atea Pharmaceuticals, Inc. reported Research And Development Expense of $148.02 million for the year ending 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +2.7% in Research And Development Expense from 2024 to 2025.
- This data is from Atea Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $2.41 million | Q1 2020: $2.82 million | Q2 2020: $7.76 million | Q3 2020: $13.60 million | Q1 2021: $26.57 million | Q2 2021: $39.80 million | Q3 2021: $43.02 million | Q1 2022: $29.63 million | Q2 2022: $19.86 million | Q3 2022: $4.91 million | Q1 2023: $28.95 million | Q2 2023: $22.06 million | Q3 2023: $28.18 million | Q1 2024: $57.58 million | Q2 2024: $34.70 million | Q3 2024: $26.16 million | Q1 2025: $29.58 million | Q2 2025: $32.28 million | Q3 2025: $38.35 million.
- Over the full 8 years of available data (2018 to 2025), Atea Pharmaceuticals, Inc.'s Research And Development Expense has grown by 2,117.6%.
- Historical annual values: Fiscal year 2025: $148.02 million | Fiscal year 2024: $144.10 million | Fiscal year 2023: $114.24 million | Fiscal year 2022: $81.94 million | Fiscal year 2021: $167.21 million | Fiscal year 2020: $38.02 million | Fiscal year 2019: $10.17 million | Fiscal year 2018: $6.68 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: